Skip to main content

Table 3 Significant markers from GWAS studies on Parkinson's disease susceptibility risk

From: A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson’s disease

Study Gender Age Discovery Follow-up # Genes Genes Variants p-value OR
M F   # SNPs Population # Cases # Ctrls Population # Cases # Ctrls
Edwards TL et al. [85] 381 224 64.56 ± 12.18 4,22,322 Caucasian-MIHG 605 621     16 PLEKHM1 rs11012 5.65×10−8 0.70
SNCA rs2736990 6.74×10−8 1.29
Satake W et al. [86]     4,35,470 Japanese 1,078 2,628 Japanese 612 14,139 4 PARK16 rs823128 4.88×10−9 1.41
rs823122 5.22×10−8 1.37
rs947211 1.52×10−12 1.30
rs823156 3.60×10−9 1.37
rs708730 2.43×10−8 1.33
4p15 rs11931532 5.13×10−9 1.24
BST1 rs12645693 8.65×10−9 1.24
rs4698412 1.78×10−8 1.24
rs4538475 3.94×10−9 1.24
4q22 rs11931074 7.35×10−17 1.37
Japanese 321 1,614 SNCA rs3857059 5.68×10−16 1.36
rs6532194 4.15×10−13 1.32
12q12 rs1994090 2.72×10−8 1.39
LRRK2 rs7304279 5.06×10−8 1.38
rs2708453 9.67×10−8 1.38
rs2046932 4.34×10−8 1.39
Sanchez JS et al. [87] 515.27 472.73 55.9±15.1 4,63,185 stage 1 USA 988 3071     3 MAPT rs393152 1.95×10−16 0.77
rs199533 1.09×10−14 0.78
rs17563986 1.67×10−14 0.78
452.98 304.02 56±11.64 Germany 757 976 SNCA rs2736990 2.24×10−14 1.23
rs3857059 3.74×10−15 1.48
rs11931074 1.62×10−14 1.46
1083.8 444.19 62.5±8.55 stage 2 USA 1528 2044 OTHERS rs823128 7.29×10−8 0.66
Do CB et al. [88] 2065.9 1360.122 64.3±10.6 5,22,782 primarily European (23andMe) 3426 29624 European descent (IPDGC) 6584 15470 11 LRRK2 rs34637584 1.82x10-28 9.615
GBA i4000416 5.17x10-21 4.048
SNCA rs356220 2.29x10-19 1.285
MAPT rs12185268 2.72x10-14 0.769
MCCC1/ LAMP3 rs10513789 2.67x10-10 0.803
             SCARB2 rs6812193 7.55x10-10 0.839
GAK rs6599389 3.87x10-8 1.311
SREBF1/RAI1 rs11868035 5.61x10-8 0.851
Burns EMH et al. [89] 1063 502 67.59±10.68 7.2 million USA (NGRC cohort) 1565 1986 White, non-Hispanics (NINDS cohort) 621,102 797 4 SNCA rs356220 1.00x10-9 1.37
HLA rs3129882 5.00×10-10 1.38
IPDGC [90] 577.75 393.255 55.9±15.1 76,89,524 USA-NIA 971 3034 US 2,807 2,215 11 SYT11 chr1:154105678 3.50×10-12 1.47
966.74 738.265 65.8±10.8 UK 1705 5200 UK 1,271 1,864 AMCSD rs6710823 6.75×10-9 1.1
446.68 295.316 56±11.6 Germany 742 944 Dutch 304 402 STK39 rs2102808 4.23×10-10 1.18
610.93 428.068 48.9±12.8 France 1039 1984 German 1153 712 MCCC1/ LAMP3 rs11711441 8.04×10-12 0.84
522.1 353.904 61.5±9.2 USA- dbGAP 876 857 French 267 363 GAK chr4:911311 3.67×10-12 1.16
BST1 rs11724635 1.21×10-16 0.87
SNCA rs356219 1.82×10 -47 1.29
HLA-DR chr6:32588205 2.24×10-14 0.78
LRRK2 rs1491942 6.01×10-14 1.27
CCDC62/ HIP1R rs12817488 3.20×10-13 1.14
MAPT rs2942168 1.47×10-28 0.79
Nalls MA et al. [69] 315 289 62.2±12.3 78,93,274 IPDGC-DC 604 4,916 IPDGC-FR 553 474 32 GBA/SYT1 rs35749011 1.37×10-29 1.824
579.18 405.82 48.9±12.8 IPDGC-FR 985 1984 IPDGC-GE 1044 871 RAB7L1/ NUCKS1 rs823118 1.66×10-16 1.122
401.53 265.466 55.7±11.5 IPDGC-GE 667 937 IPDGC-GK 944 877 SIPA1L2 rs10797576 4.87×10-10 1.131
476.16 267.84 55.6 ± 11.8 IPDGC-NE 744 2019 IPDGC-NIA 2407 2782 ACMSD/ TMEM163 rs6430538 9.13×10-20 0.875
557.52 379.485 57.8±13.2 IPDGC-NIA 937 1896     STK39 rs1474055 1.15×10-20 1.214
  1972.9 1288.095 64.2±11.2   23andMe.v2 3261 29499 IPDGC-UK 405 547   MCCC1 rs12637471 2.14×10-21 0.842
528.26 337.74 63.9±10.9 23andMe.v3 866 32538 TMEM175/ GAK/ DGKQ rs34311866 1.02×10 -43 0.786
179.02 88.976 59.9±12.1 Ash Jewish 268 178 BST1 rs11724635 9.44×10-18 1.126
362.19 211.806 57.2±12.03 HIHG 574 619 FAM47E/SCARB2 rs6812193 2.95×10-11 0.907
1306.6 649.392 58.6±11.7 NGRC 1956 1982 SNCA rs356182 4.16×10 -73 0.76
495.97 332.028 62.1±10.7 PGPD 828 852 HLA-DQB1 rs9275326 1.19×10-12 0.826
58.957 48.043 73.0 ± 5.1 CHARGE-CHS 107 3164 GPNMB rs199347 1.18×10-12 1.11
34.98 25.02 76.2 ± 10.8 CHARGE-FHS 60 3889 INPP5F rs117896735 4.34×10-13 1.624
MIR4697 rs329648 9.83×10-12 1.105
LRRK2 rs76904798 5.24×10-14 1.155
CCDC62 rs11060180 6.02×10-12 1.105
GCH1 rs11158026 5.85×10-11 0.904
TMEM229B rs1555399 6.63×10-14 0.897
VPS13C rs2414739 1.23×10-11 1.113
BCKDK/ STX1B rs14235 2.43×10-12 1.103
MAPT rs17649553 2.37×10 -48 0.769
RIT2 rs12456492 7.74×10-12 0.904
DDRGK1 rs8118008 3.04×10-11 1.111
FGF20 rs591323 6.68×10-8 0.916
Pankratz N et al. [91] NA NA NA 2633913   4,238 4,239   3,738 2,111 6 GBA E326K 5.00×10−8 1.71
GAK rs11248060 3.00×10−9 1.26
SNCA rs356220 8.00× 10 −35 1.38
rs356198 5.00×10−9 0.82
HLA reg rs2395163 3.00×10−11 0.81
MAPT rs199515 3.00×10−17 0.76
RIT2 rs12456492 2.00×10−10 1.19
Hamza TH et al. [92] 1346 654 58.34±11.93 8,11,597 Caucasian 2000 1986 NA NA NA 6 HLA-DRA rs3129882 1.90×10−10 1.26
GAK9 rs11248051 3.20×10−9 1.46
SNCA rs356220 3.40×10−11 1.38
Spencer CCA et al. [93] 1244.2 460.81 65.8 532 588 UK 1705 5175 French 1039 1984 6 SNCA rs2736990 1.36×10-27 1.23
MAPT rs393152 4.75×10-28 1.31
Vacic V et al. [94]     haplotypes Ashkenazi jews 1,130 1,807 Ashkenazi Jews 306 2583 7 MAPT rs17577094 4.51×10-10 0.64
  1. #, Number of; (D),Discovery; Ctrls, control; MIHG, Miami Institute for Human Genomics; IPDGC, International Parkinson's Disease Genomics Consortium; NGRC, NeuroGenetics Research consortium; NIA, National Institute on Aging; dbGAP, database of Genotypes and Phenotypes; HIHG, Hussman Institute of Human Genomics; PGPD, Physician Group Practice Demonstration; CHARGE-CHS, Cohorts for Health and Aging Research in Genetic Epidemiology; NA, Not applicable;